| Similar Articles |
|---|
 |
The Motley Fool
August 9, 2007
Brian Lawler |
BioMarin Gets Busy BioMarin Pharmaceutical has a busy remainder of 2007 ahead of it, including regulatory decisions, six clinical trials, and the potential for new products to enter the pipeline.   |
The Motley Fool
November 2, 2006
Brian Lawler |
BioMarin's in Good Health This biopharma has a leg up on the competition by getting its finances in order. Even with its small pipeline, BioMarin appears to be running smoothly. Investors, take note. |
The Motley Fool
February 27, 2007
Brian Lawler |
Mostly Good From BioMarin Drugmaker BioMarin updates investors on its drug pipeline and quarterly financial results. |
The Motley Fool
April 30, 2008
Brian Lawler |
BioMarin's Bodacious Earnings BioMarin raises revenue guidance for all of its marketed drugs, thanks to strong sales so far in 2008. |
The Motley Fool
April 1, 2008
Brian Lawler |
BioMarin Drug Heads Overseas One of the pharmaceutical's enzyme replacement therapy drugs gets approved in Japan. |
The Motley Fool
August 6, 2008
Brian Lawler |
BioMarin's New Drugs Mostly Hit Their Targets Near-term volatility in a drugmaker's shares can make for long-term opportunities. Such is the current case with BioMarin Pharmaceutical. |
The Motley Fool
July 31, 2009
Brian Orelli |
The Little Orphan That Could After a rough start to the year, Rule Breakers pick BioMarin Pharmaceutical is back on track. |
The Motley Fool
May 25, 2007
Brian Lawler |
BioMarin Waits for Another Drug BioMarin files a marketing application for its lead compound in development. Investors, take note. |
The Motley Fool
June 3, 2011
Brian Orelli |
FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully. |
The Motley Fool
May 17, 2005
Charly Travers |
BioMarin Bounces Back After a stumble, one biotech firm is returning to the market's good graces. BioMarin stock has shot up 30% in the past two months and is near its 52-week high. |
The Motley Fool
May 3, 2007 |
BioMarin's Big Moves: Fool by Numbers The pharmaceutical released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
February 19, 2009
Brian Orelli |
BioMarin Is Off Track Shares of BioMarin Pharmaceutical, a darling of the drug world whose shares more than doubled in 2007, come crashing down because the growth of years past seems to be waning. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
June 3, 2004
Charly Travers |
Small Drug Market, Big Hopes BioMarin is going to file for approval in the U.S. and Europe in the fourth quarter of this year after its succesful phase 3 trial of Aryplase. If the drug is approved, it would likely be on the market toward the end of 2005. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
The Motley Fool
April 16, 2004
Charly Travers |
Genzyme's Minor Disappointment The latest sales figures for Genzyme's newest drug, Aldurazyme, show that a potential growth-driving drug may be stalling out. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
The Motley Fool
October 29, 2009
Brian Orelli |
Small and Volatile, but Not for Long BioMarin is growing. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
July 12, 2010
Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
The Motley Fool
May 31, 2011
David Williamson |
Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin... |
The Motley Fool
October 8, 2007
Charly Travers |
Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics... |
The Motley Fool
March 1, 2005
Charly Travers |
From Rags to Riches One biotech's fate reveals the formula for spotting turnaround investments. BioMarin has yet to turn the corner, but that time is quickly approaching. |
The Motley Fool
November 16, 2010
Luke Timmerman |
Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
Chemistry World
July 16, 2010
Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. |
The Motley Fool
September 2, 2010
Brian Orelli |
Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases. |
The Motley Fool
June 30, 2010
Brian Orelli |
When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions. |
The Motley Fool
April 7, 2011
Brian Orelli |
Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market. |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
January 25, 2010
Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
December 13, 2010
Brian Orelli |
Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
February 18, 2005
John Bluis |
Genzyme's Acquisitions Pay Off With some of this biotech's major decisions coming to fruition, shareholders can have more confidence that management can deliver on its promises. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
May 1, 2007
Brian Lawler |
Cardiome Plays Dealmaker Cardiome signs a deal to develop one of Eli Lilly's drug candidates. Investors, take note. |
The Motley Fool
October 27, 2009
Brian Orelli |
Small Market, Small Acquisition, Still a Good Move BioMarin does everything small. |
